- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT04025125
Pathways to Cardiovascular Disease Prevention (DCRI Central and Statistical Coordinating Center)
Pathways to Cardiovascular Disease Prevention and Impact of Specialty Referral in Underrepresented Racial/Ethnic Minorities With HIV (Coordinating Center)
Studieöversikt
Status
Betingelser
Detaljerad beskrivning
Aim 1. To identify factors associated with cardiology referral in under-represented racial and ethnic minority (URM) populations with HIV and elevated cardiovascular risk Aim 2. To evaluate the association between cardiology referral and CVD outcomes in under-represented racial and ethnic populations with HIV and elevated cardiovascular risk Sub-Aim 2a. To evaluate the association between cardiology referral and guideline-based CVD prevention measures in URM populations with HIV and elevated CVD risk
Note: Aims 1 and 2-retrospective analysis with anticipated 8000 EHR records to be reviewed.
Aim 3. To identify facilitators and barriers to optimal CVD prevention
Studietyp
Inskrivning (Faktisk)
Kontakter och platser
Studieorter
-
-
North Carolina
-
Durham, North Carolina, Förenta staterna, 27707
- Duke University
-
Winston-Salem, North Carolina, Förenta staterna, 27157
- Wake Forest University Health Sciences
-
-
Ohio
-
Cleveland, Ohio, Förenta staterna, 44106
- University Hospitals Cleveland Medical Center
-
-
South Carolina
-
Charleston, South Carolina, Förenta staterna, 29425
- Medical University of South Carolina
-
-
Tennessee
-
Nashville, Tennessee, Förenta staterna, 37232-2582
- Vanderbilt University Medical Center
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Testmetod
Studera befolkning
Aims 1 and 2 not recruiting patients
Aims 3 population of interest:
- Race equals Black/African-American, American Indian/Alaska Native, Asian, Native Hawaiian/Pacific Islander, or More than one race, and/or Ethnicity equals Hispanic or Latino;
- Documented evidence of HIV positive status (HIV positive diagnosis and prescription of antiretroviral therapy (ART));
Beskrivning
Aims 1 and 2 are not recruiting as retrospective review of electronic health records.
Aims 1 and 2 Inclusion Criteria:
Patient health records may be accessed from subjects who meet the following criteria:
- Race equals Black/African-American, American Indian/Alaska Native, Asian, Native Hawaiian/Pacific Islander, or More than one race, and/or Ethnicity equals Hispanic or Latino;
- Documented evidence of HIV positive status (HIV positive diagnosis (ICD10 codes B20-B24, or ICD9 codes 042, V08) and prescription of antiretroviral therapy (ART));
- Documented evidence of elevated AtheroSclerotic CardioVascular Disease risk (ACC/AHA ASCVD 10 year risk ≥5%24, or Framingham Cardiovascular Disease 10 year risk ≥5%25) after HIV diagnosis. The date when the patient first meets either of these CVD risk thresholds and with 1 prior encounter not having CVD risk score defines the index time-point for Aim 1 of this study. These risk calculations depend on sex, age, body mass index, diabetes, current smoking, total cholesterol, HDL cholesterol, systolic blood pressure, and treatment for hypertension (defined from diagnosis codes). If cholesterol measures are not available, then body mass index may be used in place of lipids in the Framingham risk calculation; NOTE: must have a prior encounter within 365 days within health system prior to index
- Presence of a modifiable risk factor: hypertension, diabetes, elevated total cholesterol, elevated LDL cholesterol and/or tobacco use.
Aims 1 and 2 Exclusion criteria:
- Age <18 years of age or >99 years of age at index event;
- Pre-existing ASCVD prior to index event, including a previous diagnosis of any acute myocardial infarction, heart failure, acute coronary syndromes, stable or unstable angina, arterial revascularization (includes coronary arterial or peripheral), stroke, transient ischemic attack or peripheral arterial disease presumed to be of atherosclerotic origin determined by ICD codes;
- Encounter with cardiology specialist within 1 year prior to index
- Evidence of ART for pre-exposure prophylaxis (i.e., Truvada [emtricitabine/tenofovir disoproxil fumarate] or post-exposure prophylaxis (e.g., Truvada plus raltegravir) without HIV diagnosis.
Aim 3 Inclusion Criteria:
Patients:
- under-represented racial and ethnic minority (URM) populations with HIV > 40 years of age, with
- a modifiable risk factor for Cardiovascular disease (CVD) (such as hypertension, diabetes, elevated total cholesterol, high LDL cholesterol, or currently use tobacco), and/or known CVD
Providers
- HIV providers will include infectious disease physicians, Internists or advance practice practitioners who report having seen > 1 person living with HIV under their care in the last 6 months; AND
- Cardiology providers (physicians or advance practice providers) will be required to have taken care of at least 1 HIV-positive patient in the past 3 years;
Aim 3 Exclusion Criteria:
Patients
- Unwilling or unable to provide oral informed consent;
- Unable to perform an interview in English;
- Diminished capacity to give oral consent;
- Unwilling to be interviewed.
Providers
- Unable to perform an interview in English;
- Unwilling to be interviewed.
Studieplan
Hur är studien utformad?
Designdetaljer
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Proportion of patients with referral to a cardiology specialist (primary outcome for Aim 1)
Tidsram: 6 months from the date when patient met eligibility criteria for referral
|
A binary variable, with 'yes' defined if there is documented evidence that a referral is made within 6 months of becoming eligible by CVD risk score and kept within 3 months of referral, and 'no' otherwise.
Cardiology referrals with kept appointments will be ascertained from electronic health record data.
|
6 months from the date when patient met eligibility criteria for referral
|
Proportion of patients with blood pressure control (primary outcome for Aim 2)
Tidsram: Longitudinal evaluation during 5 years of follow up.
|
Blood pressure control will be defined based on prevailing guidelines during the study period (blood pressure <140/90 mmHg) and will be evaluated based on blood pressures recorded in electronic health record data.
|
Longitudinal evaluation during 5 years of follow up.
|
Proportion of patients with Cholesterol control (co-primary outcome for Aim 2)
Tidsram: Longitudinal evaluation during 5 years of follow up.
|
Cholesterol control will be defined based on prevailing guidelines during the study period and will be evaluated based on cholesterol laboratory measures recorded in electronic health record data.
|
Longitudinal evaluation during 5 years of follow up.
|
Patient perspective on facilitators and barriers to optimal CVD prevention (co-primary outcome for Aim 3)
Tidsram: Approximately 60 minutes
|
Qualitative information will be assessed from semi-structured interviews conducted with participating patients
|
Approximately 60 minutes
|
Provider perspective on facilitators and barriers to optimal CVD prevention (co-primary outcome for Aim 3)
Tidsram: Approximately 60 minutes
|
Qualitative information will be assessed from semi-structured interviews conducted with participating healthcare providers
|
Approximately 60 minutes
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Incidence of major adverse cardiovascular event, myocardial infarction (secondary outcome for Aim 2)
Tidsram: 5 years
|
Incidence of first major adverse cardiovascular event (composite of cardiovascular death and myocardial infarction) will be determined from diagnosis and/or procedure codes from electronic health record data and a query of the National Death Index (Plus).
|
5 years
|
Incidence of Stroke (secondary outcome for Aim 2)
Tidsram: 5 years
|
Incidence of first stroke event will be determined from diagnosis and/or procedure codes from electronic health record data.
|
5 years
|
Incidence of All-cause death (secondary outcome for Aim 2)
Tidsram: 5 years
|
Incidence of all-cause death will be determined from electronic health record data and a query of the National Death Index.
|
5 years
|
Samarbetspartners och utredare
Sponsor
Samarbetspartners
Utredare
- Huvudutredare: Gerald Bloomfield, MD, Duke Health
Publikationer och användbara länkar
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- Pro00101104
- 1R01MD013493-01 (U.S.S. NIH-anslag/kontrakt)
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .